Tyler Van Buren has given his Buy rating due to a combination of factors surrounding Oruka Therapeutics’ promising developments with their lead antibody, ORKA-001. The extended half-life of ...
Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA – Get Free Report) have earned a consensus rating of “Buy” from the eight ...
Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from chronic skin ...
Kronos Bio (KRON – Research Report) received a Hold rating and price target from TD Cowen analyst Tyler Van Buren yesterday. The ...
Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) is one of 39 publicly-traded companies in the “Diagnostic substances” industry, but how does it contrast to its competitors? We will compare Oruka ...
Stifel has launched its coverage on pre-clinical stage biotech Oruka Therapeutics (NASDAQ:ORKA) with a buy recommendation and a $49 price target, citing its lead candidates ORKA-001 and ORKA-002 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback